BridgeBio Pharma (FRA:2CL) Asset Impairment Charge : €0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Asset Impairment Charge?

BridgeBio Pharma's Asset Impairment Charge for the three months ended in Mar. 2025 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

BridgeBio Pharma Asset Impairment Charge Historical Data

The historical data trend for BridgeBio Pharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Asset Impairment Charge Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

12.01

0.26

BridgeBio Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

BridgeBio Pharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

BridgeBio Pharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

BBIO:USA

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines